study is the first to present the mRNA expression of Cernunnos/ XLF, which was newly identified as an NHEJ member in 2006, 6, 7 as well as of other NHEJ components including Artemis, XRCC4 and DNA ligase IV in pediatric ALL. We showed that overexpressions of NHEJ genes were closely associated with malignant leukemic cells, since elevations of NHEJ mRNA transcripts were found only in fresh ALL and in relapsed cases, but not in thalassemia, complete remission or peripheral blood of normal individuals. Elevations of NHEJ mRNAs could also be found in malignant cell lines K562 and BJAB, but not in oral cancer. Therefore, we propose that upregulation of NHEJ mRNA transcripts is a characteristic of pediatric ALL. This feature may be valuable for proper prognosis or for providing strategies for treatment of this malignancy.
The World Health Organization classification of the tumors of hematopoietic and lymphoid tissues distinguishes nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) from classical Hodgkin's lymphoma (CHL) on morphological, clinical and biological differences. 1 NLPHL accounts for approximately 5% of all Hodgkin's lymphomas and usually presents as an early stage disease, with slow progression and a favorable outcome. 2 Response to conventional therapy, when indicated, is excellent. Transformation to diffuse large B-cell lymphoma has been reported in approximately 3-5% of cases. Tumor cells, known as 'popcorn' or L&H cells, express B-cell antigens like CD20 and CD45, usually do not express CD15 and CD30 and probably are of centroblastic origin. Cytogenetic characteristics of NLPHL have been rarely reported, and were mainly obtained using molecular cytogenetic methods like fluorescent in situ hybridization (FISH) or comparative genomic hybridization (CGH). 3, 4 Between 1979 and 2004, 22 patients referred to the Centre Henri Becquerel had a diagnosis of NLPHL. A single lymph node biopsy was used for morphologic, immunologic, molecular and cytogenetic studies, including molecular cytogenetics. After an expert review, patients suspected to have atypical diffuse large B-cell lymphoma or a CHL were excluded and 13 patients with an ascertained NLPHL diagnosis were retained and are reported here. Clinical and pathological characteristics are summarized in Table 1 . Median age was 32 years (range 6-57). All patients had localized peripheral lymphadenopathy (stage I: 7 or stage II: 6). None had extra-nodal involvement or B symptoms. Five were treated at diagnosis or later, and eight patients did not receive any treatment and remained in stable disease. Median follow-up for this series is 59.8 months.
In all cases, the morphologic, cytologic and immunophenotypic features were consistent with the diagnosis of NLPHL. L&H cells expressed B-cell markers: CD79a, CD20, Oct2, Bob1 and Bcl6. Rosetting with CD57 was not constant, as reported in literature. Mum1 was expressed in 50% of cases, whereas CD30 and CD15 were not expressed. Two cases were identified as germinal center progressive transformation with features of early NLPHL. These two cases also presented typical NLPHL areas.
Good quality metaphases were obtained in all 13 patients and clonal abnormalities were identified in 12/13 (Figure 1 ).
Karyotypes are reported in Table 2 . All were complex but one, associating more than three numerical and/or structural abnormalities. Nine karyotypes were in the diploid range (46-49 chromosomes), one was hypodiploid and one tetraploid. One patient had both a diploid and a tetraploid component. As in CHL, 5 the number of abnormal metaphases was usually low as compared to the number of normal mitoses.
Recurrent chromosomal defects included a gain or a partial gain of the long arm of chromosome 1 in 10 patients, either as an isochromosome for the long arm (7/10) ( Figure 1 ) or as a translocated supernumerary long arm (3/10), 3q27 rearrangements in eight patients, loss of chromosome 4 or 4q28 rearrangements resulting in a loss of the 4q28-q32 region in six patients, loss of chromosome 7 or 7q23-q33 rearrangements in five patients, loss or partial deletion of chromosome 13 in three patients and 14q32 rearrangements in six patients.
Chromosome 9 imbalances were present in seven patients, as gain (one patient), loss (one patient), add(9)(p24) (two patients), add(9)(q22) (one patient) and 9q33-34 rearrangement (two patients). 
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The partner region involved in 3q27 rearrangements could be identified in seven cases as 5q31 in two patients and 2q23, 6q22, 9q22, 14q32 and 17q21 in one patient each. Conventional cytogenetics failed to identify the translocated material in one case.
FISH analysis could be performed on previously R-banded metaphases in nine patients. Among these, five displayed a 3q27 rearrangement and the involvement of BCL6 was confirmed by FISH in four (patients 2, 4, 9 and 11). However, whereas the translocation of patient 9 was interpreted as a t(2;3)(q23;q27), FISH showed that the telomeric part of BCL6 was translocated on a small marker chromosome, suggesting a three-way translocation. In the fifth case (patient 6), the rearrangement was telomeric to the BCL6 gene. Normal signals were found on all abnormal metaphases in 4/4 patients without 3q27 rearrangements, confirming the presence of four copies of chromosome 3 in patients 5 and in the tetraploid clone of patient 3. Search for an implication of the IgH locus in four patients with 14q32 rearrangements confirmed the involvement of the IgH gene in three cases. In patient 5, the 14q32 rearrangement found using conventional cytogenetics that is t(14;22)(q32;q11) did not involve the IgH nor the Ig l gene. An attempt to identify the IgH partner at 9q22 in patient 3 showed that the corresponding breakpoint was telomeric to RP11-346B7.
Unexpected BCL6-IgH translocations were identified in patient 4 who expressed fusion transcripts joining Im to BCL6 exon 2 and BCL6 exon1 to Cm, and in patient 11, who expressed a fusion transcript joining the BCL6 first exon to Ce but not the reciprocal Ie/BCL6-exon2 transcript, indicating a complex translocation t(3;14;6)(q27;q32;q22). The genomic breakpoint of the derivative chromosome 14 was also cloned in this patient, confirming the transcription data.
Despite the difficulty of conventional cytogenetic studies in CHL, (due to the low number of malignant cells, their low proliferation rate and the complexity of results), the cytogenetic pattern of these patients is rather well characterized, comprised of hyperdiploid metaphases, mainly in the triploid range, without any of the abnormalities usually encountered in B-cell or T-cell non-Hodgkin's lymphoma. This pattern was confirmed by molecular cytogenetics studies, including FICTION.
To date, for the same reasons the cytogenetic characterization of NLPHL remains partial, limited to some CGH data, 4 to a partial analysis using interphase FISH with probes exploring genes usually involved in B-cell lymphoma 3 and to conventional cytogenetics data from a few number of patients with NLPHL or transformed lymphoma, reported together with extensive FISH and molecular analysis. 6 Our study, where the only significant imbalances involved chromosomes 1, 4, 7, 9 and 13, does not confirm the results obtained using CGH by Franke. 4 In the present series, a gain of chromosome 1q was unexpectedly found in 10 of 12 patients, mainly represented by an isochromosome for chromosome 1 long arm. This abnormality is not frequent in other subtypes of B-cell lymphomas, present in 9/23 Burkitt's lymphomas, 20/330 diffuse large cell lymphomas, 17/303 follicular lymphomas and 12/144 CHL with cytogenetic abnormalities studied at diagnosis (C Bastard, unpublished data).
A chromosome 4q rearrangement resulting in a loss of the 4q28-qter region was present in six patients (46%). Such 4q deletions are unusual in NHL, whereas they are more frequent in CHL. 5 As reported by Wlodarska et al., 3, 6 we confirm the frequent involvement of BCL6 and immunoglobulin heavy chain genes. As underlined by these authors, 3q27 and 14q32 chromosomal defects, as detected by conventional cytogenetics, are not present in CHL. On the other hand, a recent report by Martin Subero et al. 7 demonstrates that such rearrangement can be 10 46,X,ÀX,i(1)(q10),add(2)(q12),t(3;17)(q27;q21),add(4)(p13)(q28), add(14)(q32),i(18)(q10),+mar [5] /46,XX [7] + N T N T 11 46,XY,i(1)(q10),dup(2)(p12p16),t(3;6)(q27;q22),del(7)(q22),À14,+mar [3] /46, XY,i(1)(q10),dup(2)(p12p16),t(3;6)(q27;q22),del(7)(q22),i (7) 12 47,X,ÀX,t(3;9)(q27;q33),add(5)(q31),add(7)(p21),add(7)(q31),der (13) Letters to the Editor found by FISH in a notable proportion of CHL patients. Therefore, these authors conclude that the identification of IgH and BCL6 rearrangements cannot be used to differentiate CHL from NLPHL. Whereas we agree with this conclusion when such defects are detected by FISH alone, we think that the results of a conventional cytogenetic analysis, which shows a chromosomal pattern globally different from that of CHL (mainly diploid context, iso 1q chromosome or 1q gain, higher frequency of 3q27 and 14q32 rearrangements), provides useful arguments that can contribute to distinguishing CHL from NLPHL.
To the best of our knowledge, the BCL6 partner regions that we identified here have not been previously reported, with the exception of the 14q32 region. In one of two patients carrying a t(3;5)(q27;q31), a FISH control using a break-apart probe demonstrated that the BCL6 gene was probably not involved, as the break occurred telomeric to BCL6. In this case, FISH analysis did not suggest an ABR breakpoint (no faint signal from the commercial break-apart telomeric probe).
Using interphase FISH, Renné and colleagues 8 studied the involvement of immunoglobulin genes loci in 24 patients with NLPHL and found a disruption of the IgH locus in five patients. Using triple-color FISH, they identified a BCL6-IgH translocation in all five cases and conclude that this event was recurrent in NLPHL. In our series, a single t(3;14)(q27;q32) was identified by conventional cytogenetics, whereas in two cases the same translocation could only be identified by FISH and/or molecular methods, the corresponding derivative chromosomes 3 being interpreted as add(3)(q27) and t(3;6)(q27;q22), respectively. Two other rearrangements disrupting the IgH genes involved genes located in the 9q22 and 14q23 regions, respectively, indicating that BCL6 is not the only partner of IgH translocations.
Despite a long follow-up, none of our patients transformed to diffuse large B-cell lymphoma.
This study reporting the results of conventional cytogenetic investigations performed in a series of 13 NPHL patients demonstrates that in such patients, conventional karyotypic analysis is feasible, confirms the clonal nature of the tumor and provides additional informations when compared to molecular cytogenetic methods. The identification of 3q27 and 14q32 rearrangements in a mainly diploid context confirms previously published results and demonstrates that NLPHL patients share genetic defects with NHL patients rather than with CHL patients. Hematopoietic cell-specific Lyn substrate 1 (HS1, HCLS1, LckBP1) is a 75-kDa intracellular protein expressed in cells of lymphohemopoietic origin. It was originally identified in B-lymphocytes as a major substrate of B-cell receptor (BCR)-induced phosphorylation after antigen (Ag) stimulation. Genetically modified mice confirmed that in both B and T-lymphocytes HS1 is involved in the processes of Ag-receptor-induced clonal expansion and deletion. 1 However, the specific role of HS1 remained elusive. Previous studies were not unequivocal, as they suggested various possibilities including actin-binding activity, involvement in apoptosis and a nuclear function. Likewise, the subcellular localization is unclear, as HS1 was reported to be inside the nucleus, in the cytoplasm and in the lipid rafts of B-lymphocytes. The analysis of the amino-acid sequence showed that HS1 has a modular structure and is structurally related to cortactin, a cortical actin-associated protein that modulates the dynamics of the actin cytoskeleton. This structural relationship is underscored by the existence of a putative actin-binding domain at the N-terminus of HS1 molecule. Accordingly, it has been shown recently that in
